Your browser doesn't support javascript.
loading
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Cao, Yunlong; Wang, Jing; Jian, Fanchong; Xiao, Tianhe; Song, Weiliang; Yisimayi, Ayijiang; Huang, Weijin; Li, Qianqian; Wang, Peng; An, Ran; Wang, Jing; Wang, Yao; Niu, Xiao; Yang, Sijie; Liang, Hui; Sun, Haiyan; Li, Tao; Yu, Yuanling; Cui, Qianqian; Liu, Shuo; Yang, Xiaodong; Du, Shuo; Zhang, Zhiying; Hao, Xiaohua; Shao, Fei; Jin, Ronghua; Wang, Xiangxi; Xiao, Junyu; Wang, Youchun; Xie, Xiaoliang Sunney.
Affiliation
  • Cao Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.
  • Wang J; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.
  • Jian F; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Xiao T; School of Life Sciences, Peking University, Beijing, P. R. China.
  • Song W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Yisimayi A; College of Chemistry and Molecular Engineering, Peking University, Beijing, P. R. China.
  • Huang W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Li Q; Joint Graduate Program of Peking-Tsinghua-NIBS, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, P. R. China.
  • Wang P; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • An R; School of Life Sciences, Peking University, Beijing, P. R. China.
  • Wang J; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Wang Y; School of Life Sciences, Peking University, Beijing, P. R. China.
  • Niu X; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
  • Yang S; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
  • Liang H; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Sun H; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Li T; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Yu Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Cui Q; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Liu S; College of Chemistry and Molecular Engineering, Peking University, Beijing, P. R. China.
  • Yang X; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Du S; Tsinghua-Peking Center for Life Sciences, Beijing, P. R. China.
  • Zhang Z; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Hao X; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
  • Shao F; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
  • Jin R; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
  • Wang X; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
  • Xiao J; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
  • Wang Y; Beijing YouAn Hospital, Capital Medical University, Beijing, P. R. China.
  • Xie XS; School of Life Sciences, Peking University, Beijing, P. R. China.
Nature ; 602(7898): 657-663, 2022 02.
Article in En | MEDLINE | ID: mdl-35016194
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neutralization Tests / Antibodies, Neutralizing / Immune Evasion / SARS-CoV-2 / Antibodies, Viral Limits: Humans Language: En Journal: Nature Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neutralization Tests / Antibodies, Neutralizing / Immune Evasion / SARS-CoV-2 / Antibodies, Viral Limits: Humans Language: En Journal: Nature Year: 2022 Type: Article